NKTX on Nasdaq

Nkarta Therapeutics (United States)

We are a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer ("NK") cell therapies.4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

2015Founded1

Compare with BullFrog AI Holdings, Inc., SOLIGENIX, INC. or Serina Therapeutics, Inc., or pick any stock.

  • TickerNKTX on Nasdaq1
  • Industrybiotechnology industry1
  • HeadquartersSouth San Francisco, California1
  • Websitewww.nkartatx.com
  • Incorporated inDE3
  • Business address1150 Veterans Boulevard, South San Francisco, Ca 940803
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer ("NK") cell therapies. Our company was founded on the belief that engineered NK cell therapies can transform the lives of patients by offering therapies that are clinically meaningful, broadly accessible and unencumbered by the safety concerns often associated with other cell therapy approaches. Our lead pipeline program is NKX019, a chimeric antigen receptor-natural killer ("CAR NK") product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases. Our CAR NK platform enables an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. We have developed proprietary technologies designed to generate an abundant supply of NK cells, increase NK cell recognition of target antigens, and enhance…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-33.3%Return on equity5
-$89.9MFree cash flow5

Financial statements

Revenue675$0 in 2025
0$50.0K$100.0K$150.0K2019: $115.0K$115.0K20192024: $0$020242025: $0$02025
Operating income6891075-$122.0M in 2025+446% since 2019
-$150.0M-$100.0M-$50.0M02019: -$22.3M-$22.3M20192020: -$51.5M-$51.5M2020+130%2021: -$86.4M-$86.4M2021+68%2022: -$119.0M-$119.0M2022+38%2023: -$131.7M-$131.7M2023+11%2024: -$128.2M-$128.2M2024−3%2025: -$122.0M-$122.0M2025−5%
Net income6891075-$104.1M in 2025+394% since 2019
-$150.0M-$100.0M-$50.0M02019: -$21.1M-$21.1M20192020: -$91.4M-$91.4M2020+333%2021: -$86.1M-$86.1M2021−6%2022: -$113.8M-$113.8M2022+32%2023: -$117.5M-$117.5M2023+3%2024: -$108.8M-$108.8M2024−7%2025: -$104.1M-$104.1M2025−4%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Research and development$90.4M$96.7M
General and administrative$31.6M$31.4M
Total operating expenses$122.0M$128.2M
Loss from operations-$122.0M-$128.2M
Interest income$15.5M$19.3M
Other income, net$2.4M$87.0K
Total other income, net$17.9M$19.4M
Net Income (Loss)-$104.1M-$108.8M
Net unrealized (loss) gain on investments-$267.0K$666.0K
Comprehensive loss-$104.4M-$108.1M
Net loss per share, basic-$1.41-$1.60
Net loss per share, diluted-$1.41-$1.60
Weighted average shares outstanding used in computing net loss per share, basic74.0M shares67.9M shares
Weighted average shares outstanding used in computing net loss per share, diluted74.0M shares67.9M shares

Compare Nkarta Therapeutics (United States) with another company

Leadership

Who has led Nkarta Therapeutics (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Paul J. Hastings2021–now

President

  1. Nadir Mahmood2024–now

Chief financial officer

  1. Matthew Plunkett2020
20202025
Board members and other officers (23)

Timeline

  1. Jan 12, 2021New chief executive Paul J. Hastings becomes CEO13
  2. 2015Founded Founded1

Filings

288 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 48 major events, 137 insider forms, 44 large holders, 39 other. The latest 20:

  1. Aug 10, 202610-Q EDGAR
  2. Aug 10, 20268-K EDGAR
  3. Jun 22, 20264 EDGAR
  4. Jun 11, 20264 EDGAR
  5. Jun 11, 20268-K EDGAR
  6. Jun 11, 20264 EDGAR
  7. Jun 11, 20264 EDGAR
  8. Jun 11, 20264 EDGAR
  9. Jun 11, 20264 EDGAR
  10. Jun 11, 20264 EDGAR
  11. Jun 11, 20264 EDGAR
  12. Jun 11, 20264 EDGAR
  13. May 19, 2026SCHEDULE 13D/A EDGAR
  14. May 12, 202610-Q EDGAR
  15. May 12, 20268-K EDGAR
  16. Apr 23, 2026ARS EDGAR
  17. Apr 23, 2026DEFA14A EDGAR
  18. Apr 23, 2026DEF 14A EDGAR
  19. Apr 3, 2026EFFECT EDGAR
  20. Apr 3, 2026424B5 EDGAR

The 288 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

52 open-market trades by officers, directors and large owners since October 2021: 4 buys and 48 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 18, 2026HASTINGS PAUL JChief Executive OfficerSale1,776$2.71$4.8KForm 4
Jan 15, 2026HASTINGS PAUL JChief Executive OfficerSale26,046$2.07$53.9KForm 4
Jan 15, 2026Mahmood NadirPresidentSale5,649$2.07$11.7KForm 4
Jun 18, 2025HASTINGS PAUL JChief Executive OfficerSale1,790$1.79$3.2KForm 4
Jan 15, 2025Shook DavidSee RemarksSale8,638$2.20$19.0KForm 4
Jan 15, 2025Levin AlyssaSee RemarksSale5,838$2.20$12.8KForm 4
Jan 15, 2025Brandenberger RalphChief Technical OfficerSale7,447$2.20$16.4KForm 4
Jan 15, 2025HASTINGS PAUL JChief Executive OfficerSale17,378$2.20$38.2KForm 4
Jan 15, 2025Hager Alicia J.Chief Legal OfficerSale9,584$2.20$21.1KForm 4
Jul 16, 2024Hager Alicia J.Chief Legal OfficerSale3,396$8.00$27.2KForm 4
Jun 18, 2024Trager JamesChief Scientific OfficerSale456$5.60$2.6KForm 4
Jun 18, 2024HASTINGS PAUL JChief Executive OfficerSale1,770$5.60$9.9KForm 4
Jun 18, 2024Shook DavidSee RemarksSale456$5.60$2.6KForm 4
Jun 18, 2024Hager Alicia J.Chief Legal OfficerSale727$5.60$4.1KForm 4
Jun 18, 2024Brandenberger RalphChief Technical OfficerSale229$5.60$1.3KForm 4
Mar 27, 2024RA CAPITAL MANAGEMENT, L.P.DirectorBuy3,000,000$10.00$30.0MForm 4
Mar 27, 2024George SimeonDirectorBuy2,000,000$10.00$20.0MForm 4
Mar 1, 2024Brandenberger RalphChief Technical OfficerSale8,367$12.51$104.7KForm 4
Feb 12, 2024Trager JamesChief Scientific OfficerSale4,143$12.00$49.7KForm 4
Jan 16, 2024Shook DavidSee RemarksSale3,552$8.74$31.0KForm 4

All 52 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Ra Capital Management, L.P.10,805,129$30.6M0.3%No change
BlackRock, Inc.6,300,212$17.8M0.0%+1,791,739
NEA Management Company, LLC3,568,781$10.1M0.6%No change
Samsara Biocapital, LLC3,507,666$9.9M0.8%No change
SR One Capital Management, LP3,333,333$9.4M0.9%No change
GSK plc3,150,732$8.9M1.5%No change
Monaco Asset Management SAM2,373,400$6.7M2.5%−148,532
Vanguard Capital Management LLC2,226,415$6.3M0.0%+214,994
Citadel Advisors LLC2,174,745$6.2M0.0%+390,751
Two Sigma Investments, LP1,873,293$5.3M0.0%−174,083
Wasatch Advisors LP1,577,847$4.5M0.0%No change
State Street Corp1,286,109$3.6M0.0%+48,635
Geode Capital Management, LLC1,285,507$3.6M0.0%+17,592
Renaissance Technologies LLC1,177,652$3.3M0.0%−554,720
Aqr Capital Management LLC1,054,251$3.0M0.0%+458,525
AWM Investment Company, Inc.906,000$2.6M0.2%No change
Blackstone Inc.747,044$2.1M0.0%New
Marshall Wace, Llp673,010$1.9M0.0%New
Panagora Asset Management Inc583,249$1.7M0.0%+299,039
Jpmorgan Chase & Co562,980$1.6M0.0%−12,021
Peapod Lane Capital LLC549,923$1.6M1.1%−126,289
Alyeska Investment Group, L.P.484,840$1.4M0.0%−1,600,000
Dimensional Fund Advisors LP483,211$1.4M0.0%+136,618
Nuveen, LLC469,555$1.3M0.0%+23,757
Goldman Sachs Group Inc433,982$1.2M0.0%+48,982

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54